<scp>SQuID</scp> (subcutaneous insulin in diabetic ketoacidosis) <scp>II</scp>: Clinical and operational effectiveness
In this single-center study, we observed excellent fidelity, equivalent or superior safety, and clinical and operational effectiveness with SQuID compared to IV insulin. The SQuID protocol has become the de facto default pathway for treatment of LTM DKA. Since inception of SQuID, ICU admissions in LTM DKA have decreased 33%.
Authors
- Paulina Cruz‐Bravo
- Ryan M. Schneider (ORCID: https://orcid.org/0000-0001-7122-1079)
- Richard T. Griffey (ORCID: https://orcid.org/0000-0002-6279-7380)
- Gina LaRossa
- Rachel M. Ancona (ORCID: https://orcid.org/0000-0001-6514-0897)
- Laura Frawley
- Julianne Yeary (ORCID: https://orcid.org/0000-0001-7773-2486)
- Margo Girardi
- Taylor Kaser (ORCID: https://orcid.org/0000-0003-2415-914X)
- Dan Suarez
- Michael Lehmkuhl
Institutions
- Barnes-Jewish Hospital (US)
- Washington University in St. Louis (US)
- Saint Louis University Hospital (US)
Publication Details
- Journal
- Academic Emergency Medicine
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1111/acem.15020
- Citations
- 6
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.30
Funders
- Agency for Healthcare Research and Quality